Alpine Immune Sciences - ALPN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $52.33
  • Forecasted Upside: -19.45%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$64.97
+0 (0.00%)

This chart shows the closing price for ALPN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alpine Immune Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPN

Analyst Price Target is $52.33
▼ -19.45% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Alpine Immune Sciences in the last 3 months. The average price target is $52.33, with a high forecast of $65.00 and a low forecast of $18.00. The average price target represents a -19.45% upside from the last price of $64.97.

This chart shows the closing price for ALPN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Alpine Immune Sciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
6/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
6/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024WedbushReiterated RatingNeutral ➝ Neutral$65.00Low
4/16/2024TD CowenReiterated RatingBuy ➝ HoldLow
4/12/2024SVB LeerinkDowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00Low
4/11/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
4/11/2024HC WainwrightDowngradeBuy ➝ NeutralLow
4/11/2024WedbushDowngradeOutperform ➝ NeutralLow
4/11/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00Low
4/11/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00Low
4/11/2024Wolfe ResearchReiterated RatingOutperform ➝ Peer PerformLow
4/9/2024GuggenheimInitiated CoverageBuy$55.00Low
3/19/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$30.00 ➝ $47.00Low
3/19/2024WedbushReiterated RatingOutperform ➝ Outperform$47.00Low
3/19/2024OppenheimerReiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.00Low
3/19/2024HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $50.00Low
2/15/2024Wolfe ResearchInitiated CoverageOutperform$44.00Low
1/26/2024WedbushBoost TargetOutperform ➝ Outperform$26.00 ➝ $35.00Low
12/22/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $32.00Low
11/15/2023WedbushReiterated RatingOutperform ➝ Outperform$26.00Low
11/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$19.00 ➝ $22.00Low
11/3/2023WedbushBoost TargetOutperform ➝ Outperform$19.00 ➝ $26.00Low
11/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$17.00 ➝ $30.00Low
10/17/2023Berenberg BankInitiated CoverageBuy$18.00Low
10/4/2023Royal Bank of CanadaInitiated CoverageOutperform$19.00Low
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
9/11/2023OppenheimerBoost TargetOutperform ➝ Outperform$14.00 ➝ $22.00Low
9/1/2023WedbushReiterated RatingOutperform ➝ Outperform$19.00Low
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
8/15/2023WedbushBoost TargetOutperform ➝ Outperform$17.00 ➝ $19.00Low
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $17.00Low
3/24/2023WedbushReiterated RatingOutperformLow
3/24/2023HC WainwrightBoost Target$8.00 ➝ $11.00Low
1/19/2023Morgan StanleyInitiated CoverageOverweight$17.00Low
11/21/2022SVB LeerinkInitiated CoverageOutperform$15.00Low
10/24/2022OppenheimerLower TargetOutperform$17.00 ➝ $14.00Low
10/24/2022HC WainwrightLower Target$21.00 ➝ $8.00Low
9/15/2022WedbushBoost Target$25.00Low
5/17/2022WedbushReiterated RatingOutperform$22.00Low
5/13/2022HC WainwrightReiterated RatingBuy$21.00Medium
3/7/2022OppenheimerLower Target$19.00 ➝ $17.00High
6/24/2021HC WainwrightReiterated RatingBuy$21.00Medium
6/3/2021HC WainwrightReiterated RatingBuy$21.00High
3/19/2021OppenheimerReiterated RatingBuy$19.00High
12/21/2020HC WainwrightInitiated CoverageBuy$21.00Low
8/26/2020CowenInitiated CoverageOutperformLow
8/12/2020OppenheimerReiterated RatingBuy$19.00High
8/11/2020Piper SandlerLower TargetOverweight$21.00 ➝ $18.00High
6/19/2020Piper SandlerBoost Target$8.00 ➝ $21.00Low
6/19/2020WedbushBoost TargetOutperform$10.00 ➝ $22.00Low
6/8/2020OppenheimerReiterated RatingBuy$12.00High
5/26/2020WedbushReiterated RatingOutperform$10.00Medium
5/26/2020LADENBURG THALM/SH SHReiterated RatingBuy$17.00Medium
5/26/2020Piper SandlerReiterated RatingOverweight$8.00Medium
5/14/2020OppenheimerReiterated RatingBuy$12.00High
3/31/2020WedbushReiterated RatingOutperformMedium
11/13/2019Piper Sandler CompaniesLower TargetOverweight$8.00Low
(Data available from 6/14/2019 forward)

News Sentiment Rating

1.29 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 12 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 29 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 15 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Alpine Immune Sciences logo
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $64.97
Low: $64.97
High: $64.97

50 Day Range

MA: $62.79
Low: $34.91
High: $64.97

52 Week Range

Now: $64.97
Low: $8.33
High: $65.00

Volume

N/A

Average Volume

1,917,072 shs

Market Capitalization

$4.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Alpine Immune Sciences?

The following Wall Street sell-side analysts have issued reports on Alpine Immune Sciences in the last twelve months: Berenberg Bank, Guggenheim, HC Wainwright, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, TD Cowen, Wedbush, and Wolfe Research.
View the latest analyst ratings for ALPN.

What is the current price target for Alpine Immune Sciences?

9 Wall Street analysts have set twelve-month price targets for Alpine Immune Sciences in the last year. Their average twelve-month price target is $52.33, suggesting a possible downside of 19.5%. Morgan Stanley has the highest price target set, predicting ALPN will reach $65.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $18.00 for Alpine Immune Sciences in the next year.
View the latest price targets for ALPN.

What is the current consensus analyst rating for Alpine Immune Sciences?

Alpine Immune Sciences currently has 8 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALPN, but not buy more shares or sell existing shares.
View the latest ratings for ALPN.

What other companies compete with Alpine Immune Sciences?

How do I contact Alpine Immune Sciences' investor relations team?

Alpine Immune Sciences' physical mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company's listed phone number is (206) 788-4545 and its investor relations email address is [email protected]. The official website for Alpine Immune Sciences is www.alpineimmunesciences.com. Learn More about contacing Alpine Immune Sciences investor relations.